Clinical research partner dMed has completed a series B round that included returning investor Lilly Asia Ventures as it seeks to expand internationally.

Invest NI is to continue its funding relationship wit Crescent Capital and Techstart Ventures, the latter of which has previously operated two $2m funds aimed at spinouts.

Takeda is set to emerge with almost 26% of Phathom Pharmaceuticals, which has licensed one of its gastrointestinal disease drugs, and which is targeting $158m.

ProMedica and Pacira are both in line for exits after surgical implant producer Tela Bio filed for an initial public offering.

Sinovation Ventures led a round for the Fosun-backed medical services platform developer that raised in excess of $14.1m in its series B round.

Spun out of University of Duisburg-Essen and University of Düsseldorf, Abalos has raised funding to kickstart development of arenavirus-based immunotherapies.

Intel Capital was among the participants in a round that lifted the total raised by rare disease-focused drug developer Healx to nearly $70m.

Boehringer Ingelheim Venture Fund co-led a $13.3m round for the immuno-oncoclogy startup, which was spun out of University of Duisburg-Essen’s and University of Düsseldorf.

The cancer therapy developer boosted a series B round led by Novo and backed by Celgene to $75.2m, with both corporates contributing to the latest tranche.

Jackson Laboratory cancer drug spinout Cyteir Therapeutics extended its series B round thanks to investors including Osage University Partners and Novo Holdings.